ADMA Biologics, Inc.
ADMA
$9.37
-$0.17-1.78%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -16.56% | -8.20% | 35.55% | 6.46% | 27.19% |
| Total Depreciation and Amortization | -3.15% | -10.12% | 1.14% | -1.70% | 4.52% |
| Total Amortization of Deferred Charges | 0.52% | -3.05% | 15.88% | 6.25% | -15.79% |
| Total Other Non-Cash Items | 270.55% | -74.80% | -45.48% | 55.59% | -3.82% |
| Change in Net Operating Assets | -276.97% | 141.05% | 39.66% | -62.23% | 59.47% |
| Cash from Operations | -49.29% | 63.44% | 168.10% | -37.12% | 207.44% |
| Capital Expenditure | 11.29% | -134.59% | 92.46% | -493.23% | 48.48% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -106.56% | -- | 100.00% | -452.63% |
| Cash from Investing | -193.84% | 971.01% | 98.08% | -468.58% | 46.46% |
| Total Debt Issued | -100.00% | -- | -100.00% | 150.00% | -- |
| Total Debt Repaid | 0.00% | 0.00% | 99.38% | -151.56% | -- |
| Issuance of Common Stock | -94.05% | 36.74% | 10.54% | -81.15% | 1,943.56% |
| Repurchase of Common Stock | 78.57% | -1,391.83% | 62.23% | -1,915.28% | 83.52% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 99.65% | -353.70% | -- |
| Cash from Financing | -190.38% | -11.10% | 67.23% | -58,068.75% | 100.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -104.22% | 92.51% | 190.81% | -254.88% | 159.20% |